RU95104898A - Имидазолсодержащие ингибиторы фарнезид-протеинтрансферазы, способ лечения связанных с ней заболеваний - Google Patents
Имидазолсодержащие ингибиторы фарнезид-протеинтрансферазы, способ лечения связанных с ней заболеванийInfo
- Publication number
- RU95104898A RU95104898A RU95104898/04A RU95104898A RU95104898A RU 95104898 A RU95104898 A RU 95104898A RU 95104898/04 A RU95104898/04 A RU 95104898/04A RU 95104898 A RU95104898 A RU 95104898A RU 95104898 A RU95104898 A RU 95104898A
- Authority
- RU
- Russia
- Prior art keywords
- independently
- gis
- phenyl
- represented
- alkyl
- Prior art date
Links
- 0 CC1C(C)(C)C(C*)c2ccccc2C1 Chemical compound CC1C(C)(C)C(C*)c2ccccc2C1 0.000 description 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/04—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0207—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
Ингибирование фарнезил-трансферазы, которая представляет собой фермент, ответственный за экспрессию онкогена ras, осуществляют с помощью соединений общей формулы, данной в описании, или их энантиомеров, диастереомеров, фармацевтически приемлемых солей, пролекарственных предшественников, и сольватов.
Claims (1)
- Ингибирование фарнезил-трансферазы, которая представляет собой фермент, ответственный за экспрессию онкогена ras, осуществляют с помощью соединений общей формулы, данной в описании, или их энантиомеров, диастереомеров, фармацевтически приемлемых солей, пролекарственных предшественников, и сольватов.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22115394A | 1994-03-31 | 1994-03-31 | |
US29291694A | 1994-08-19 | 1994-08-19 | |
US292916 | 1994-08-19 | ||
US221153 | 1994-08-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
RU95104898A true RU95104898A (ru) | 1996-12-27 |
Family
ID=26915545
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU95104898/04A RU95104898A (ru) | 1994-03-31 | 1995-03-30 | Имидазолсодержащие ингибиторы фарнезид-протеинтрансферазы, способ лечения связанных с ней заболеваний |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP0675112A1 (ru) |
JP (1) | JPH07304750A (ru) |
KR (1) | KR950032174A (ru) |
CN (1) | CN1112117A (ru) |
AU (1) | AU1615895A (ru) |
CA (1) | CA2146059A1 (ru) |
CZ (1) | CZ82195A3 (ru) |
FI (1) | FI951554A (ru) |
HU (1) | HUT72440A (ru) |
IL (1) | IL113196A0 (ru) |
NO (1) | NO951266L (ru) |
PL (1) | PL307950A1 (ru) |
RU (1) | RU95104898A (ru) |
Families Citing this family (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5439918A (en) | 1994-03-14 | 1995-08-08 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5652257A (en) * | 1994-09-29 | 1997-07-29 | Merck & Co., Inc. | Heterocycle-containing inhibitors of farnesyl-protein transferase |
US5661161A (en) * | 1994-09-29 | 1997-08-26 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
AU708620B2 (en) * | 1995-03-29 | 1999-08-05 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5627202A (en) * | 1995-03-29 | 1997-05-06 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
EP0837857A4 (en) * | 1995-03-29 | 1998-08-05 | Merck & Co Inc | FARNESYL-PROTEIN TRANSFERASE INHIBITORS |
US5624936A (en) * | 1995-03-29 | 1997-04-29 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
CA2226623A1 (en) * | 1995-07-13 | 1997-01-30 | University Of Cincinnati | Compounds useful in the treatment of neurofibromatosis |
US5703241A (en) * | 1995-10-16 | 1997-12-30 | Merck & Co., Inc. | Inhibitor of farnesyl-protein transferase |
AU7597596A (en) * | 1995-11-06 | 1997-05-29 | University Of Pittsburgh | Inhibitors of protein isoprenyl transferases |
WO1997018813A1 (en) * | 1995-11-22 | 1997-05-29 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US6028201A (en) * | 1996-01-30 | 2000-02-22 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US6090948A (en) * | 1996-01-30 | 2000-07-18 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
EP0880320A4 (en) * | 1996-01-30 | 1999-06-16 | Merck & Co Inc | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE |
US5965578A (en) * | 1996-04-03 | 1999-10-12 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
CA2249601A1 (en) * | 1996-04-03 | 1997-10-23 | Thorsten E. Fisher | Inhibitors of farnesyl-protein transferase |
JP2000507597A (ja) * | 1996-04-03 | 2000-06-20 | メルク エンド カンパニー インコーポレーテッド | ファルネシルタンパク質トランスフェラーゼ阻害剤 |
CA2249641A1 (en) * | 1996-04-03 | 1997-10-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
EP0891335A4 (en) * | 1996-04-03 | 2001-08-16 | Merck & Co Inc | FARNESYL-PROTEIN TRANSFERASE INHIBITORS |
CZ298749B6 (cs) | 1996-10-18 | 2008-01-16 | Vertex Pharmaceuticals Incorporated | Inhibitory serinových proteáz a farmaceutické prostředky s jejich obsahem |
US6015817A (en) * | 1996-12-05 | 2000-01-18 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5932590A (en) * | 1996-12-05 | 1999-08-03 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5977134A (en) * | 1996-12-05 | 1999-11-02 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5972966A (en) * | 1996-12-05 | 1999-10-26 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
TW527355B (en) * | 1997-07-02 | 2003-04-11 | Bristol Myers Squibb Co | Inhibitors of farnesyl protein transferase |
CA2312366A1 (en) * | 1997-12-04 | 1999-06-10 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US6562823B1 (en) * | 1998-07-02 | 2003-05-13 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
JP2002519427A (ja) * | 1998-07-02 | 2002-07-02 | メルク エンド カムパニー インコーポレーテッド | プレニル蛋白トランスフェラーゼ阻害薬 |
US6316436B1 (en) * | 1998-12-08 | 2001-11-13 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
DE19937394A1 (de) * | 1999-08-07 | 2001-02-08 | Merck Patent Gmbh | Fluorenderivate |
EP1288202A4 (en) * | 2000-05-11 | 2003-07-02 | Banyu Pharma Co Ltd | N-ACYLTETRAHYDROISOQUINOLINE DERIVATIVES |
SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
WO2002094019A1 (en) | 2001-05-22 | 2002-11-28 | Eisai Co., Ltd | Highly purified antiendotoxin compound |
US7074921B2 (en) | 2001-11-13 | 2006-07-11 | Bristol Myers Squibb Company | Process for the preparation of 3,7-disubstituted-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine compounds |
MY148123A (en) | 2003-09-05 | 2013-02-28 | Vertex Pharma | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
AU2004282148A1 (en) | 2003-10-10 | 2005-04-28 | Vertex Pharmaceuticals Incoporated | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
WO2006123182A2 (en) | 2005-05-17 | 2006-11-23 | Merck Sharp & Dohme Limited | Cyclohexyl sulphones for treatment of cancer |
US7964624B1 (en) | 2005-08-26 | 2011-06-21 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
AR055395A1 (es) | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
PE20070335A1 (es) | 2005-08-30 | 2007-04-21 | Novartis Ag | Benzimidazoles sustituidos y metodos para su preparacion |
GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
CA2643688A1 (en) | 2006-02-27 | 2007-08-30 | Vertex Pharmaceuticals Incorporated | Co-crystals and pharmaceutical compositions comprising the same |
KR20080112303A (ko) | 2006-03-16 | 2008-12-24 | 버텍스 파마슈티칼스 인코포레이티드 | 중수소화 c형 간염 프로테아제 억제제 |
ES2654847T3 (es) | 2006-04-19 | 2018-02-15 | Novartis Ag | Compuestos de benzoxazol y benzotiazol sustituidos en 6-O y métodos para inhibir la señalización CSF-1R |
FR2900573B1 (fr) * | 2006-05-05 | 2014-05-16 | Sederma Sa | Nouvelles compositions cosmetiques renfermant au moins un peptide contenant au moins un cycle aromatique bloque |
WO2008039327A2 (en) | 2006-09-22 | 2008-04-03 | Merck & Co., Inc. | Method of treatment using fatty acid synthesis inhibitors |
US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
AU2008204380B2 (en) | 2007-01-10 | 2013-08-15 | Msd Italia S.R.L. | Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors |
US8759353B2 (en) | 2007-02-27 | 2014-06-24 | Vertex Pharmaceuticals Incorporated | Co-crystals and pharmaceutical compositions comprising the same |
WO2008106058A2 (en) | 2007-02-27 | 2008-09-04 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
CN101679266B (zh) | 2007-03-01 | 2015-05-06 | 诺华股份有限公司 | Pim激酶抑制剂及其应用方法 |
BRPI0812159A2 (pt) | 2007-05-21 | 2017-05-02 | Novartis Ag | inibidores de csf-1r, composições e métodos de uso |
US8389553B2 (en) | 2007-06-27 | 2013-03-05 | Merck Sharp & Dohme Corp. | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
US8492546B2 (en) | 2007-08-30 | 2013-07-23 | Vertex Pharmaceuticals Incorporated | Co-crystals and pharmaceutical compositions comprising the same |
EP2413932A4 (en) | 2009-04-01 | 2012-09-19 | Merck Sharp & Dohme | INHIBITORS OF AKT ACTIVITY |
JP6073677B2 (ja) | 2009-06-12 | 2017-02-01 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | 縮合複素環式化合物およびそれらの使用 |
BR112012008849A2 (pt) | 2009-10-14 | 2015-09-22 | Schering Corp | composto, composição farmacêutica, e, uso de um composto |
CA2784807C (en) | 2009-12-29 | 2021-12-14 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
BR112012023021A2 (pt) | 2010-03-16 | 2016-05-31 | Dana Farber Cancer Inst Inc | compostos de indazol e seus usos |
JP6043285B2 (ja) | 2010-08-02 | 2016-12-14 | サーナ・セラピューティクス・インコーポレイテッドSirna Therapeutics,Inc. | 低分子干渉核酸(siNA)を用いたカテニン(カドヘリン結合型タンパク質)β1(CTNNB1)遺伝子発現のRNA干渉媒介性阻害 |
HUE044815T2 (hu) | 2010-08-17 | 2019-11-28 | Sirna Therapeutics Inc | Hepatitisz B vírus (HBV) génexpressziójának RNS-interferencia közvetített gátlása, rövid interferáló nukleinsav (SINS) alkalmazásával |
EP2608669B1 (en) | 2010-08-23 | 2016-06-22 | Merck Sharp & Dohme Corp. | NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS |
EP2613782B1 (en) | 2010-09-01 | 2016-11-02 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as erk inhibitors |
WO2012036997A1 (en) | 2010-09-16 | 2012-03-22 | Schering Corporation | Fused pyrazole derivatives as novel erk inhibitors |
US9260471B2 (en) | 2010-10-29 | 2016-02-16 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) |
WO2012087772A1 (en) | 2010-12-21 | 2012-06-28 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
EP2687531B1 (en) | 2011-03-18 | 2016-07-13 | ONO Pharmaceutical Co., Ltd. | Tetrahydrocarboline derivative |
US20140045847A1 (en) | 2011-04-21 | 2014-02-13 | Piramal Enterprises Limited | Crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation |
WO2013063214A1 (en) | 2011-10-27 | 2013-05-02 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
WO2013074986A1 (en) | 2011-11-17 | 2013-05-23 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-jun-n-terminal kinase (jnk) |
EP3919620A1 (en) | 2012-05-02 | 2021-12-08 | Sirna Therapeutics, Inc. | Short interfering nucleic acid (sina) compositions |
US9233979B2 (en) | 2012-09-28 | 2016-01-12 | Merck Sharp & Dohme Corp. | Compounds that are ERK inhibitors |
US10112927B2 (en) | 2012-10-18 | 2018-10-30 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
US9758522B2 (en) | 2012-10-19 | 2017-09-12 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
WO2014063054A1 (en) | 2012-10-19 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof |
BR112015012295A8 (pt) | 2012-11-28 | 2023-03-14 | Merck Sharp & Dohme | Uso de um inibidor de wee1, e, kit para identificar um paciente com câncer |
BR112015013611A2 (pt) | 2012-12-20 | 2017-11-14 | Merck Sharp & Dohme | composto, e, composição farmacêutica |
EP2951180B1 (en) | 2013-01-30 | 2018-05-02 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as hdm2 inhibitors |
EP3041938A1 (en) | 2013-09-03 | 2016-07-13 | Moderna Therapeutics, Inc. | Circular polynucleotides |
WO2015058126A1 (en) | 2013-10-18 | 2015-04-23 | Syros Pharmaceuticals, Inc. | Heteroaromatic compounds useful for the treatment of prolferative diseases |
JP6491202B2 (ja) | 2013-10-18 | 2019-03-27 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | サイクリン依存性キナーゼ7(cdk7)の多環阻害剤 |
US9862688B2 (en) | 2014-04-23 | 2018-01-09 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged janus kinase inhibitors and uses thereof |
WO2015164614A1 (en) | 2014-04-23 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Janus kinase inhibitors and uses thereof |
JO3589B1 (ar) | 2014-08-06 | 2020-07-05 | Novartis Ag | مثبطات كيناز البروتين c وطرق استخداماتها |
AU2015371251B2 (en) | 2014-12-23 | 2020-06-11 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
WO2016160617A2 (en) | 2015-03-27 | 2016-10-06 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
EP3307728A4 (en) | 2015-06-12 | 2019-07-17 | Dana Farber Cancer Institute, Inc. | ASSOCIATION THERAPY USING TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS |
EP3347018B1 (en) | 2015-09-09 | 2021-09-01 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
JOP20190055A1 (ar) | 2016-09-26 | 2019-03-24 | Merck Sharp & Dohme | أجسام مضادة ضد cd27 |
JP7160833B2 (ja) | 2017-04-13 | 2022-10-25 | サイロパ ビー.ブイ. | 抗sirpアルファ抗体 |
WO2019094311A1 (en) | 2017-11-08 | 2019-05-16 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
WO2019148412A1 (en) | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Anti-pd-1/lag3 bispecific antibodies |
TW202000658A (zh) * | 2018-02-16 | 2020-01-01 | 美商星座製藥公司 | P300/cbp hat 抑制劑及其使用方法 |
WO2020033282A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
EP3833667B1 (en) | 2018-08-07 | 2024-03-13 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2376860A1 (fr) | 1977-01-07 | 1978-08-04 | Parcor | Tetrahydro-4,5,6,7 thieno (2,3-c) et (3,2-c) pyridines, leur procede de preparation et leur application therapeutique |
DE3752373T2 (de) | 1986-10-13 | 2004-03-25 | Asahi Kasei Kogyo K.K. | Pyridin-derivate |
JPH02193971A (ja) | 1989-01-20 | 1990-07-31 | Yamanouchi Pharmaceut Co Ltd | トリ置換―2,3,4,5―テトラヒドロベンズアゼピン誘導体とその中間体 |
US5352705A (en) * | 1992-06-26 | 1994-10-04 | Merck & Co., Inc. | Inhibitors of farnesyl protein transferase |
PT725790E (pt) * | 1993-10-25 | 2001-08-30 | Parke Davis & Co | Inibidores tetra e penta-peptidicos substituidos da proteina farnesil transferase |
KR100362338B1 (ko) * | 1993-11-05 | 2003-04-08 | 워너-램버트 캄파니 | 단백질:파르네실트랜스퍼라아제의치환디-및트리펩티드억제제 |
-
1995
- 1995-03-30 HU HU9500934A patent/HUT72440A/hu unknown
- 1995-03-30 AU AU16158/95A patent/AU1615895A/en not_active Abandoned
- 1995-03-30 RU RU95104898/04A patent/RU95104898A/ru unknown
- 1995-03-30 IL IL11319695A patent/IL113196A0/xx unknown
- 1995-03-31 CZ CZ95821A patent/CZ82195A3/cs unknown
- 1995-03-31 CA CA002146059A patent/CA2146059A1/en not_active Abandoned
- 1995-03-31 JP JP7075486A patent/JPH07304750A/ja active Pending
- 1995-03-31 EP EP95302188A patent/EP0675112A1/en not_active Withdrawn
- 1995-03-31 CN CN95103978A patent/CN1112117A/zh active Pending
- 1995-03-31 NO NO951266A patent/NO951266L/no unknown
- 1995-03-31 KR KR1019950007235A patent/KR950032174A/ko not_active Application Discontinuation
- 1995-03-31 FI FI951554A patent/FI951554A/fi not_active Application Discontinuation
- 1995-03-31 PL PL95307950A patent/PL307950A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
AU1615895A (en) | 1995-10-12 |
HU9500934D0 (en) | 1995-05-29 |
IL113196A0 (en) | 1995-06-29 |
PL307950A1 (en) | 1995-10-02 |
HUT72440A (en) | 1996-04-29 |
FI951554A (fi) | 1995-10-01 |
NO951266D0 (no) | 1995-03-31 |
CN1112117A (zh) | 1995-11-22 |
EP0675112A1 (en) | 1995-10-04 |
NO951266L (no) | 1995-10-02 |
JPH07304750A (ja) | 1995-11-21 |
KR950032174A (ko) | 1995-12-20 |
CZ82195A3 (en) | 1996-09-11 |
FI951554A0 (fi) | 1995-03-31 |
CA2146059A1 (en) | 1995-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU95104898A (ru) | Имидазолсодержащие ингибиторы фарнезид-протеинтрансферазы, способ лечения связанных с ней заболеваний | |
TR200201505T2 (tr) | Terapötik maddeler olarak pirazolopirimidinler | |
CY1108019T1 (el) | Ενωσεις πυριμιδινης | |
NO20003561D0 (no) | Bicykliske heteroaromatiske forbindelser som protein tyrosinkinase inhibitorer | |
EA200500174A1 (ru) | Новые производные бензимидазола, полезные в качестве антипролиферативных агентов | |
DE69330714T2 (de) | Chinuclidine derivate als substanz p antagonisten | |
EA200500853A1 (ru) | 2,4,6-тризамещённые пиримидины, являющиеся ингибиторами фосфотидилинозитол(pi)-3-киназы, и их применение при лечении рака | |
EA200701780A1 (ru) | Противоопухолевое средство | |
EE200000472A (et) | Kasvajavastased toimeained | |
ATE277072T1 (de) | Sapogenin derivate zur behandlung von kognitiven störungen | |
DE69413118D1 (de) | Benzolsulfonamid-Derivate zur Behandlung der Blaseninstabilität | |
EA200000996A1 (ru) | Конденсированные с арилом азаполициклические соединения | |
ATE390923T1 (de) | Topoisomerase-giftmittel | |
ATE219085T1 (de) | 2-beta-substituierte-6-alkylidenpenizillansäure derivate als beta-laktamase inhibitoren | |
TW200635592A (en) | Pyridyl-substituted spiro-hydantoin compounds and use thereof | |
DE69828197D1 (de) | Amidderivate zur behandlung neurodegenerativer erkrankungen der netzhaut | |
AR043271A1 (es) | Compuestos de dihidropironas con heterociclos unidos y su uso en composicines farmaceuticas que poseen actividad inhibidora de hiv proteasa | |
WO2002018353A3 (en) | Oxazolidinone chemotherapeutic agents | |
EA200201184A1 (ru) | Применение акрилоильных производных дистамицина для лечения опухолей, связанных с высокими уровнями глутатиона | |
MX2022016516A (es) | Piridina-1,5-dionas que exhiben inhibición de proteínas cinasas activadas por mitogenos que interaccionan con cinasas activadas (mnk) y su método de uso. | |
TR200201145T2 (tr) | Hidromisin türevleri | |
DE69320911D1 (de) | Chinuclidine derivate als squalen synthase inhibitore | |
MX2022015986A (es) | Derivados de aminopirimidinilo. | |
ES2141134T3 (es) | Derivados de carbamoil pirrolidona para el tratamiento de la depresion y de los trastornos cerebrovasculares. | |
WO2023141432A3 (en) | Apol1 inhibitors and methods of use |